tailieunhanh - EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Đang chuẩn bị liên kết để tải về tài liệu:
EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors

An Nhàn 89 13 pdf

The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), and subsequent treatments received. | EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Đang chuẩn bị liên kết để tải về tài liệu:
EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Study on rate and some risk factors for egfr mutation in 152 patients with lung adenocarcinoma at Bachmai hospital

Targeting TKI resistance in non - small cell lung cancer patients caused by secondary EGFR T790m mutation

Potential genetic modifiers for somatic EGFR mutation in lung cancer: A metaanalysis and literature review

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: An economic analysis

Đang chuẩn bị liên kết để tải về tài liệu: EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors